NASDAQ
CG Oncology, Inc. (CGON)
♥ 657 Thanks from members
CG Oncology, Inc. (CGON) demonstrates strong clinical and regulatory momentum with its lead bladder cancer therapy, cretostimogene, though tempered by widening quarterly net losses, missed revenue estimates, and high asset concentration risks.